Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Subarachnoidal Hemorrhage, Intacranial H...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

During the first week after an acute cerebral injury, neurologic clinical exam is often irrelevant, limited by sedation use or spontaneous consciousness disorders. Hence, neurological monitoring of brain oxygen consumption, metabolic disorders, electrical activity is used to follow and prevent delayed cerebral injuries. Among those instruments, numerous are often described: intra cranial pressure monitoring, brain tissue oxygen pressure monitoring, scalp electroencephalography, continuous electroencephalography and Near infrared Red Spectroscopy (NIRS). Even if the value of some of those technologies are well known, many remain part of a research domain. Here we will not only try to study the correlation between different cerebral autoregulation's index described in the scientific literature but also will we try to identify and describe EEG and cardiorespiratory changes during the first week following brain injury. The objective of this study is to investigate the pathophysiology of acute brain injury and explore potent biomarkers of multimodal monitoring during the first week following acute brain injury.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Other: Study the evolution and correlation between cerebral autoregulation index — Objective n°1: Study the correlation between autoregulation index: The investigators will look for a correlation between several auroregulation index such as the PRx, ORx and Cox. Objective n°2: Evaluation and detection of EEG prognostic patterns: The investigators will look for quantitaive EEG changes during the early phase of acute brain injuries.

Primary Outcomes

  • Correlation between ORx and PRx (Multimodal neuro monitoring is used from 1 to 15 days after the acute brain injury.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-01-01
Completion: 2030-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospices Civils de Lyon
Contact Information
Study Contact:
Dr Baptiste Balança
04 72 35 75 76
baptiste.balanca@chu-lyon.fr
Baptiste Balança
04 72 35 75 76
baptiste.balanca@chu-lyon.fr
Hopital Pierre Wertheimer
Interventions
  • Other: Study the evolution and correlation between cerebral autoregulation index — Objective n°1: Study the correlation between autoregulation index: The investigators will look for a correlation between several auroregulation index such as the PRx, ORx and Cox. Objective n°2: Evaluation and detection of EEG prognostic patterns: The investigators will look for quantitaive EEG changes during the early phase of acute brain injuries.
Study Locations (1 sites)
Hopital Pierre Wertheimer, France, Bron 69500 France
Eligibility Criteria
Inclusion Criteria: * \- Patients hospitalized in neurologic critical care in Wertheimer Hospital, Bron * Monitored with the CNS MOBERG® monitoring system Exclusion Criteria: * \- Refusal to participate * Patients under legal protection
Conditions Open Angle Glaucoma (OAG)
Phase Not Applicable
Enrollment 55
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

DSLT demonstrates a ≥ 20% reduction of IOP from pre-treatment baseline in POAG patients naïve of previous glaucoma treatment at 12 months.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: DSLT enables newly diagnosed patients to remain well controlled and off medications — DSLT enables newly diagnosed patients to remain well controlled and off medications

Primary Outcomes

  • Success of IOP Reduction Through DSLT Utilization (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-31
Completion: 2027-12-31
Eligibility
Age: 30 Years and older
Sex: ALL
Volunteers: false
Enrollment: 55 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Barnet Dulaney Perkins Eye Centers
Collaborators: Alcon, a Novartis Company
Principal Investigators:
  • Christine Funke, Medical Doctor (PRINCIPAL_INVESTIGATOR) - Barnet Dulaney Perkins Eye Centers
Contact Information
Study Contact:
Derek J Arnson, Master of Education
4804201005
derek.arnson@researchavp.com
Christine Funke, Medical Doctor
4804201005
christine.funke@BDPEC.com
Derek J Arnson, Master of Education
4804201005
derek.arnson@researchavp.com
Barnet Dulaney Perkins Eye Centers
Interventions
  • Device: DSLT enables newly diagnosed patients to remain well controlled and off medications — DSLT enables newly diagnosed patients to remain well controlled and off medications
Study Locations (1 sites)
Barnet Dulaney Perkins Eye Centers, Mesa, Arizona 85206 United States
Eligibility Criteria
Inclusion Criteria: * Primary open angle glaucoma * Patients age 30 or greater with an IOP of 18-26 mmHg * Mild to moderate POAG patients (mild or moderate according to the AAO PPP Guidelines) * DSLT procedure Exclusion Criteria: * History of prior glaucoma treatment - this includes past medication use (in either eye), previous lasers or incisional surgery * Angle closure patients * Ocular Hypertension * Baseline VF MD of worse than -12dB * Uncontrolled systemic microvascular disease (eg. HTN, DM) * Subjects with peri-limbal findings (e.g. melanosis, tumors, extensive pterygium, significant senile arcus and pterygium)
Conditions Type 2 Diabetes, Whole Body Vibration, M...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this interventional study is to investigate the effect of whole body vibration therapy on muscle oxygenation, vibration sensation, functional capacity and balance in individuals with Type 2 diabetes. The main questions aimed to be answered are: * Does whole body vibration therapy affect peripheral muscle oxygenation? * Does whole body vibration therapy improve vibration sense, functional capacity and balance compared to aerobic exercise? Participants' muscle oxygenation, vibration sensation, functional capacity and balance parameters will be assessed. They will participate in a whole body vibration therapy or aerobic training program.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Other: Whole Body Vibration — Each exercise session will be performed with a frequency of 30 Hz and an amplitude of 2 mm. Participants are in a 110° squat position on the platform (the degree will be adjusted using a goniometer). Participants will exercise for 16 minutes from week one to week three, 20 minutes from week four to week six and 24 minutes from week seven to week eight, respectively (8 iterations and 1 minute of vibration with 1 minute interval between each iteration)
  • Other: Aerobic Exercise — From week one to week three, from week four to week six and from week seven to week eight, the participants will exercise for 30 minutes (5 minutes of running at 60-70% of heart rate and 5 minutes of active rest at 30-45% of maximum heart rate), 42 minutes (7 minutes of running at 60-70% of heart rate and 7 minutes of active rest at 30-45% of maximum heart rate) and 60 minutes (10 minutes of running at 60-70% of heart rate and 10 minutes of active rest at 30-45% of maximum heart rate). The exercise sessions consist of warm-up, main program and cool-down phases.

Primary Outcomes

  • Muscle Oxygenation (8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-01
Completion: 2025-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ankara Medipol University
Collaborators: Gazi University
Contact Information
Study Contact:
Selcan Suicmez, Research Asst.
+90 312 444 20 10
selcansuicmez@hotmail.com
Zeynep Hazar, Prof. Dr.
+90 312 216 26 21
zhazar@gazi.edu.tr
Zeynep Hazar, Prof. Dr.
+90 312 216 26 21
zhazar@gazi.edu.tr
Gazi University, Faculty of Health, Department of Physiotherapy and Rehabilitation
Interventions
  • Other: Whole Body Vibration — Each exercise session will be performed with a frequency of 30 Hz and an amplitude of 2 mm. Participants are in a 110° squat position on the platform (the degree will be adjusted using a goniometer). Participants will exercise for 16 minutes from week one to week three, 20 minutes from week four to week six and 24 minutes from week seven to week eight, respectively (8 iterations and 1 minute of vibration with 1 minute interval between each iteration)
  • Other: Aerobic Exercise — From week one to week three, from week four to week six and from week seven to week eight, the participants will exercise for 30 minutes (5 minutes of running at 60-70% of heart rate and 5 minutes of active rest at 30-45% of maximum heart rate), 42 minutes (7 minutes of running at 60-70% of heart rate and 7 minutes of active rest at 30-45% of maximum heart rate) and 60 minutes (10 minutes of running at 60-70% of heart rate and 10 minutes of active rest at 30-45% of maximum heart rate). The exercise sessions consist of warm-up, main program and cool-down phases.
Study Locations (1 sites)
Gazi University, Faculty of Health, Department of Physiotherapy and Rehabilitation, Ankara, Çankaya Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Volunteering to participate in the research * Being diagnosed with type 2 diabetes * 18 years of age or older * HbA1c level to be 6.5-10% * Having a clinical history of diabetes between 2-10 years * Receiving oral hypoglycemic agent treatment * At least three HbA1c measurements within 12 to 24 months * Hemoglobin variability score (HVS) \<50 * Being able to walk independently * Mini mental test score ≥ 24 * Vastus lateralis muscle adipose tissue thickness \<20mm * BMI \<30 kg/m2 Exclusion Criteria: * Previous or concurrent psychiatric, neurological, orthopedic or systemic illness * Use of insulin in treatment * Diabetic neuropathy * Foot ulcer * Participation in any exercise program in the last 6 months * History of major hypoglycemia in the last 12 months * Working or have worked in a job with high exposure to mechanical whole body vibrations * Conditions that may contraindicate whole body vibration (deep vein thrombosis, severe osteoporosis, active cancer, implanted medical devices, etc.) * Hearing, vision and perception problems that may affect research results
Conditions Breast Cancer, Invasive Carcinoma of Bre...
Phase PHASE2
Enrollment 144
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to evaluate 5 days vs. 9 days of whole breast radiation.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Radiation Therapy — Undergo hypofractionated radiation therapy

Primary Outcomes

  • 24-month Mean breast overall satisfaction Breast - Q scores with 5 fractions of radiation is non-inferior in patient reported outcomes. (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-05-21
Completion: 2033-05
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 144 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Utah
Principal Investigators:
  • Matthew R. Poppe, MD (PRINCIPAL_INVESTIGATOR) - Huntsman Cancer Institute
Contact Information
Study Contact:
Rachel Kingsford
801-585-0115
rachel.kingsford@hci.utah.edu
David Samuel
801-587-4713
david.samuel@hci.utah.edu
Rachel Kingford
801-585-0115
rachel.kingsford@hci.utah.edu
Huntsman Cancer Institute/University of Utah
Interventions
  • Radiation: Radiation Therapy — Undergo hypofractionated radiation therapy
Study Locations (1 sites)
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah 84112 United States
Eligibility Criteria
Inclusion Criteria: * Female participant aged ≥ 18 years. --Participants must have at least one of the following risk factors: * Grade 3 invasive histology * Estrogen receptor positivity less than 5% * Lymphovascular invasion * Invasive margins \<2mm on surgical pathology * DCIS final positive margin * Extensive intraductal component * Age ≤ 50 years * Tumor size \> 2 cm * Histologically confirmed invasive carcinoma or Ductal Carcinoma In Situ (DCIS) of the breast. * Breast cancer stage (AJCC v8) T0-3, N0, M0. T0 N0 is allowed if whole breast radiation is recommended by the treating physician. * Lumpectomy within 84 days of the start of radiation. * ECOG Performance Status ≤ 2, or KPS ≥ 50 * Negative inked histologic margins from lumpectomy, with the exception of a focus of positive margin at the pectoralis fascia. * Negative pregnancy test for participants of childbearing potential, evidence of permanent surgical sterilization, or post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: * \< 50 years of age: * Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and * Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution * ≥ 50 years of age: * Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or * Had radiation-induced menopause with last menses \>1 year ago; or * Had chemotherapy-induced menopause with last menses \>1 year ago * Sexually active participants of childbearing potential must agree to use highly effective method of contraception (defined in Section 5.4.1) during the course of radiation and for 30 days after radiation. * Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines. Exclusion Criteria: * Bilateral breast cancer. * Prior radiation therapy to the chest. * Prior chemotherapy. * Recurrent disease. * Known metastases or node positive. * Major chest surgery which is expected to impact study participation 8 weeks prior to starting study drug. * Prior breast malignancy in either breast. * The diagnosis of any other malignancy which, in the opinion of the Investigator, is likely to negatively impact the subject's safety or ability to participate in the study. * Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions: * Cardiovascular disorders: * Congestive heart failure New York Heart Association Class III or IV, unstable angina pectoris, serious cardiac arrhythmias. * Stroke (including transient ischemic attack \[TIA\]), myocardial infarction (MI), or other ischemic events, or thromboembolic event (e.g., deep venous thrombosis, pulmonary embolism) within 3 months before the first dose. * Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow, social/ psychological issues, etc.) * Significant post lumpectomy complications requiring an unplanned re-operation for surgical complications or admission for IV antibiotics. Re-operation for margins evaluation or nodal evaluation is acceptable. Draining of a seroma is not considered a complication unless it has become infected. * Breast neuroendocrine carcinoma or sarcoma histology. * Radiation sensitizing disease or condition (e.g. connective tissue disease, li fremani, etc.). * Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study. * Participants receiving concurrent radiation sensitizing medications or therapies.
Conditions Breast Cancer
Phase PHASE1
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical research study is to find the best dose of the drugs cyclophosphamide and axatilimab that can be given in combination with the standard dose of retifanlimab to patients with metastatic TNBC.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Cyclophosphamide — Given by mouth
  • Drug: Axatilimab (SNDX-6352) — Given by IV
  • Drug: Retifanlimab — Given by IV

Primary Outcomes

  • Safety and Adverse Events (AEs) (Through study completion; an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-08-13
Completion: 2029-01-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Principal Investigators:
  • Bora Lim, MD (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Bora Lim, MD
(713) 745-0689
blim@mdanderson.org
Angela Alexander
832-450-5265
Bora Lim, MD
713-745-0689
blim@mdanderson.org
The University of Texas M. D. Anderson Cancer Center
Interventions
  • Drug: Cyclophosphamide — Given by mouth
  • Drug: Axatilimab (SNDX-6352) — Given by IV
  • Drug: Retifanlimab — Given by IV
Study Locations (1 sites)
The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Patients must have histologically confirmed malignancy that is metastatic or locally recurrent unresectable and for which standard curative or palliative measures do not exist or are no longer effective. * Patients must have histologically or cytologically confirmed non-IBC triple negative breast cancers, defined here as ER\<1%, PR\<1% and HER2 negative per ASCO CAP 2018 guideline. OR * Inflammatory breast cancer (IBC) confirmed according to international consensus criteria that is ER\<20% and PR\<20%. * At least 1 week since prior chemotherapy or radiation therapy * Age .18 years. * Has at least one measurable lesion per RECIST 1.1 * ECOG performance status . 2 (Karnofsky . 60%,). * Patients must have adequate organ and marrow function as defined below: * absolute neutrophil count . 1,000/mcL * hemoglobin \>9 mg/dL * platelets . 100,000/mcL * total bilirubin . institutional upper limit of normal (ULN) * AST(SGOT)/ALT(SGPT) . 3 \~ institutional ULN; . 5 \~ institutional ULN if confirmed liver metastasis and elevation is deemed to be directly due to metastasis. * Creatinine clearance .30 mL/min (measured by the Cockcroft-Gault equation\*). * Ability to understand and the willingness to sign a written informed consent * . Cognitively impaired subjects will not be enrolled in this study. * Negative serum pregnancy test within 72 hours of receiving the first dose of the study medication for women of childbearing potential as per institutional guidelines. * Subjects of childbearing potential must be willing to use highly effective birth control methods or be surgically sterile or abstain from heterosexual activity for the course of the study. Women must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following: * Postmenopausal (no menses in greater than or equal to 12 consecutive months). * History of hysterectomy or bilateral salpingo-oophorectomy. * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy). * History of bilateral tubal ligation or another surgical sterilization procedure. * Approved methods of birth control are as follows: Hormonal contraception (i.e., birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. * Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of all study drug administration. Exclusion Criteria: * Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> Grade 1) except for alopecia. Note: Subjects may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to \> Grade 2 for at least 3 months prior to \[enrollment/Cycle 1 Day 1\] and managed with standard of care treatment) that the investigator deems related to previous anticancer therapy, including: Chemotherapyinduced neuropathy, Fatigue, Residual toxicities from prior IO treatment: Grade 1 or Grade 2 endocrinopathies which may include: Hypothyroidism/hyperthyroidism, Type I diabetes, Hyperglycemia, Adrenal insufficiency, Adrenalitis and Skin hypopigmentation (vitiligo) * Patients with a history of interstitial lung disease (past or current) or active, non-infectious pneumonitis. * Patients with active autoimmune disease requiring systemic immunosuppression with corticosteroids (\> 10 mg/day of prednisone or equivalent) or immunosuppressive drugs within 2 years before the first dose of study treatment. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide, axatilimab, retifanlimab used in study. * Patients with uncontrolled intercurrent illness. Medical history or complication considered inappropriate for participation in the study, or a serious physical or psychiatric disease, the risk of which may be increased by participation in the study in the investigator's opinion. * Patients with active infections requiring systemic antibiotics or antifungal or antiviral treatment within 14 days of C1D1 study treatment. * Patients with known active Hepatitis B or Hepatitis C infection. Testing is required to establish eligibility. Active Hepatitis B infection is defined as a positive Hepatitis B surface antigen and positive Hepatitis B core antibody test. Active Hepatitis C infection is defined assay. * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. * Patients with known HIV infection, defined as positive for HIV1/2 antibodies. Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. * Patients with psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women are excluded from this study due to potential for teratogenic or abortifacient effects. * Patients who are cancer survivors other than cured non-melanomatous skin cancer or cured cervical carcinoma in situ and thyroid cancer will be excluded from the study as other cancers can recur. * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. * Patients with active brain metastasis if treatment is warranted. Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)- directed therapy shows no evidence of progression. * Patients with known leptomeningeal disease, defined as unequivocal imaging or cytologyproven disease. * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better, and EF greater than 45% despite best supportive cae. * Patients with a history or presence of screening ECG test that is clinically significantly abnormal in the investigator's opinion. Patients with a prolonged Qtc interval \> 480 milliseconds (corrected by Fridericia or Bazett formula are excluded, but medically controlled arrhythmias are allowed. * Patients with a history of significant cardiac event within 6 months of C1D1. Significant cardiac events include baseline NYHA class III/IV cardiac disease, acute myocardial infarction, severe/unstable angina, cardiomyopathy, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, critical conduction delay, transient ischemic attack or pulmonary embolism. * Patients who are receiving any other investigational agents.
Conditions Breast Carcinoma
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial studies how well a chemotherapy-induced peripheral neuropathy (CIPN) decision aid works in improving chemotherapy decision making among patients with breast cancer. CIPN involves numbness or tingling in the hands or feet and is a debilitating side effect of several commonly used classes of cancer drugs. CIPN symptoms are typically minor at first but can progress with continued treatment to severe symptoms that can affect long-term function, falls risk, and quality of life. Symptoms sometimes resolve after treatment but in patients who experienced CIPN, symptoms are still present 1 year post-treatment in about two-thirds of patients and 3 years post-treatment in approximately half of the patients. Previous studies indicate patients lack awareness of long-term CIPN symptoms. A decision aid that provides information about permanent CIPN, that helps patients understand their treatment priorities, and prepares them for a discussion with their medical oncologist may lead to improvements in treatment decision making, satisfaction with decision making, and ultimately increase patient's achievement of their treatment goals.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Informational Intervention — Given CIPN DecisionAid
  • Other: Survey Administration — Ancillary studies

Primary Outcomes

  • Change in decision preparedness (up to 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-13
Completion: 2026-07
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Michigan Rogel Cancer Center
Principal Investigators:
  • Daniel L Hertz (PRINCIPAL_INVESTIGATOR) - University of Michigan Rogel Cancer Center
Contact Information
Study Contact:
Daniel Hertz
734-763-0015
DLHertz@med.umich.edu
Daniel L. Hertz
734-763-0015
DLHertz@med.umich.edu
University of Michigan Comprehensive Cancer Center
Daniel L. Hertz
University of Michigan Comprehensive Cancer Center
Interventions
  • Other: Informational Intervention — Given CIPN DecisionAid
  • Other: Survey Administration — Ancillary studies
Study Locations (1 sites)
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 United States
Eligibility Criteria
Inclusion Criteria: * Patients with breast cancer * Currently receiving cycle three of taxane treatment * Approval of medical oncologist to enroll patient * Experiencing any CIPN based on enrollment screening question, "In the last 7 days, what was the severity of your numbness or tingling in your hands or feet at its worst? None, Mild, Moderate, Severe, Very Severe. Patient is eligible if their answer is anything except "None" * Access to a smartphone or similar device that can complete CIPN DecisionAid via Qualtrics while in the waiting room Exclusion Criteria: * Inability to read or speak English
Conditions Major Depressive Disorder
Phase PHASE3
Enrollment 850
Locations 106 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: NBI-1065845 — NBI-1065845 tablets

Primary Outcomes

  • Number of Participants with Treatment-emergent Adverse Events (TEAEs) (Baseline through Week 52)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-04-16
Completion: 2030-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 850 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Neurocrine Biosciences
Principal Investigators:
  • Clinical Development Lead (STUDY_DIRECTOR) - Neurocrine Biosciences
Contact Information
Study Contact:
Neurocrine Medical Information Call Center
1-877-641-3461
medinfo@neurocrine.com
Interventions
  • Drug: NBI-1065845 — NBI-1065845 tablets
Study Locations (106 sites)
Neurocrine Clinical Site, Huntsville, Alabama 35801 United States
Neurocrine Clinical Site, Bryant, Arkansas 72022 United States
Neurocrine Clinical Site, Little Rock, Arkansas 72204 United States
Neurocrine Clinical Site, Glendale, California 91206 United States
Neurocrine Clinical Site, Los Angeles, California 90025 United States
Neurocrine Clinical Site, Oceanside, California 92056 United States
Neurocrine Clinical Site, Orange, California 92866 United States
Neurocrine Clinical Site, Pico Rivera, California 90660 United States
Neurocrine Clinical Site, San Diego, California 92103-8229 United States
Neurocrine Clinical Site, San Francisco, California 94107 United States
Eligibility Criteria
Key Inclusion Criteria: * Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder. * Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression. * Participant must have been taking oral antidepressants for at least 8 weeks prior to screening. * Willing and able to comply with all study procedures and restrictions in the opinion of the investigator. Key Exclusion Criteria: * A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than MDD. * Are considered by the investigator to be at imminent risk of suicide or injury to self or others. Other protocol defined inclusion and exclusion criteria apply.
Conditions Asthma
Phase PHASE2
Enrollment 252
Locations 137 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 18 to 70 years old * Have had moderate-to-severe asthma for at least 12 months that is not well controlled * Have been taking their regular maintenance treatment(s) for asthma over the last 12 months All participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 12 weeks. We will compare the experiences of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective. Participants will be involved in this study for about 7.5 months. During this time, they will have 9 visits at the study clinic.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: PF-07275315 — subcutaneous injection
  • Other: Placebo — subcutaneous injection

Primary Outcomes

  • Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (Week 12)
  • Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), and AEs/SAEs leading to treatment discontinuation (Baseline through Week 24)
  • Clinically significant, treatment-related laboratory abnormalities (Baseline through Week 24)
  • Clinically significant, treatment-related abnormalities in vital signs (Baseline through Week 24)
  • Clinically significant, treatment-related electrocardiogram (ECG) abnormalities (Baseline through Week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-05-20
Completion: 2027-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 252 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pfizer
Principal Investigators:
  • Pfizer CT.gov Call Center (STUDY_DIRECTOR) - Pfizer
Contact Information
Study Contact:
Pfizer CT.gov Call Center
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com
Interventions
  • Drug: PF-07275315 — subcutaneous injection
  • Other: Placebo — subcutaneous injection
Study Locations (137 sites)
Velocity Clinical Research, Mobile, Mobile, Alabama 36608 United States
Chandler Clinical Trials, Chandler, Arizona 85224 United States
Antelope Valley Clinical Trials, Lancaster, California 93534 United States
NewportNativeMD, Inc., Newport Beach, California 92663 United States
California Medical Research Associates, Northridge, California 91324 United States
Allergy and Asthma Associates of Santa Clara Valley Research Center, San Jose, California 95117 United States
Allergy & Asthma Clinical Research, Walnut Creek, California 94598 United States
Colorado ENT & Allergy, Colorado Springs, Colorado 80923 United States
Cpcc-Research Llc, East Point, Georgia 30344 United States
Christie Clinic - University, Champaign, Illinois 61820 United States
Eligibility Criteria
Inclusion Criteria: Must meet the following asthma criteria: 1. History of persistent, moderate-to-severe asthma for at least 12 months prior to screening. 2. Must have experienced at least 1 asthma exacerbation requiring treatment with systemic steroids (oral or parenteral) for 3 days or more within 12 months of the screening visit. 3. At least 2 of the 3 pre-bronchodilator FEV1 values collected in the run-in period and the mean of the of pre-bronchodilator FEV1 values collected in the run-in period are ≥30% to \<80% of predicted normal values. 4. Positive bronchodilator responsiveness as evidenced by increase in FEV1 of at least 12% and 200 mL for spirometry conducted during screening period. 5. Maintenance (controller) treatment that minimally includes a medium to high dose ICS - LABA combination consistent with GINA Step 4/5 (either Track 1 or Track 2) for 12 months prior to the screening visit and at a stable dose for at least 3 months prior to the screening visit. 6. ACQ-5 score of ≥1.5 at screening visit and prior to randomization. Other Inclusion Criteria: 7. Body mass index between 18 40 kg/m2 at screening. Exclusion Criteria: Medical Conditions: 1. Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. 2. Evidence of lung disease(s) other than asthma, either clinical evidence, spirometry, or imaging (Chest X-ray, CT, MRI) within 12 months of the screening visit, as per local standard of care, including but not limited to: Chronic obstructive pulmonary disease, Other emphysematous lung disease such as alpha-1 antitrypsin disease, Cystic fibrosis, Emphysema, Idiopathic pulmonary fibrosis, Churg-Strauss syndrome, Allergic bronchopulmonary aspergillosis, Sarcoidosis 3. Diagnosed with any of the following acute or chronic infections or infection history: * Active helminth or parasitic infection requiring treatment within 2 weeks prior to screening; * Infection requiring hospitalization or systemic (parenteral) antimicrobial therapy within 60 days prior to Day 1; * Any infection judged to be an opportunistic infection or clinically significant by the investigator, within 6 months prior to Day 1. Prior/Concomitant Therapy: 4. Prior or current use of any prohibited concomitant medication(s) or unwillingness or inability to use a required concomitant medication(s). 5. Prior or concurrent treatment with either approved or experimental biologic treatment (such as inhibitors of IL-4, IL-13, IL-33/ST2, IL-4Rα, TSLP, IL-5, OX40/OX40L or IgE) or targeted synthetic drugs (such as JAK inhibitors) for the treatment of asthma or other type 2 inflammatory diseases, including but not limited to: AD, EoE, CRS. 6. Treatment with any dose level of systemic (oral, injectable, or intraarticular) corticosteroids within 28 days of the screening visit. 7. Prior (within 12 weeks prior to screening) or planned concomitant treatment with immunoglobulin supplementation (eg, IV Ig or SC Ig). 8. History of anaphylaxis to antibody therapeutic or to PF-07275315 or to the excipients of the formulated drug products. 9. Bronchial thermoplasty within the previous 24 months. Prior/Concurrent Clinical Study Experience: 10. Administration of an investigational drug product within 30 days or 5 half lives preceding the screening visit (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during participation in this study.
Conditions Advanced Solid Tumor, Advanced Breast Ca...
Phase PHASE1
Enrollment 234
Locations 21 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BMS-986500 — Specified dose of specified days
  • Drug: Palbociclib — Specified dose on specified days
  • Drug: Fulvestrant — Specified dose on specified days

Primary Outcomes

  • Number of Participants With Dose Limiting Toxicities (DLTs) (Up to Day 28 From Last Dose)
  • Number of Participants With Adverse Events (AEs) (Up to Day 28 From Last Dose)
  • Number of Participants With Serious Adverse Events (SAEs) (Up to Day 28 From Last Dose)
  • Number of Participants With AEs Leading to Discontinuation (Up to Day 28 From Last Dose)
  • Number of Participants With TEAEs Leading to Death (Up to Day 28 From Last Dose)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-08-01
Completion: 2028-12-14
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 234 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bristol-Myers Squibb
Principal Investigators:
  • Bristol-Myers Squibb (STUDY_DIRECTOR) - Bristol-Myers Squibb
Contact Information
Study Contact:
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com, www.BMSStudyConnect.com
855-907-3286
Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Mehmet Akce, Site 0001
205-975-0832
University of Alabama at Birmingham
Interventions
  • Drug: BMS-986500 — Specified dose of specified days
  • Drug: Palbociclib — Specified dose on specified days
  • Drug: Fulvestrant — Specified dose on specified days
Study Locations (21 sites)
University of Alabama at Birmingham, Birmingham, Alabama 35294-3300 United States
Providence St. Jude Medical Center, Fullerton, California 92835 United States
Marin Cancer Care, Greenbrae, California 94904 United States
Moores Cancer Center, La Jolla, California 92093 United States
Hoag Memorial Hospital Presbyterian, Newport Beach, California 92663 United States
Local Institution - 0008, Aurora, Colorado 80045 United States
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
Washington University School of Medicine, St Louis, Missouri 63110 United States
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03756 United States
Roswell Park Cancer Institute, Buffalo, New York 14263 United States
Eligibility Criteria
Inclusion Criteria: * Participants must be ≥ 18 years of age. * Participants must have histologically confirmed diagnosis of a locally advanced, unresectable, or metastatic solid tumor malignancy. * Participants must have a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Participants must have a stable Eastern Cooperative Oncology Group Performance Status of 0 or 1. * For Part 2A only, participants must have CCNE1-amplified ovarian cancer Exclusion Criteria: * Participants must not have an active brain metastasis. * Participants must not have impaired cardiac function or clinically significant cardiac disease. * Participants must not have bleeding disorder or any history of clinically significant bleeding within the prior 3 months. * Participants must not have Grade ≥ 2 peripheral neuropathy. * Other protocol-defined Inclusion/Exclusion criteria apply.
Conditions Hyperlipidemias, Diabetes, Depression, P...
Phase NA
Enrollment 68000
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if the implementation of the WE CARE social determinants of health (SDOH) screening and referral intervention with an antiracist lens in primary care settings can lead to a meaningful decrease in chronic disease by monitoring conditions such as hypertension, diabetes, depression, hyperlipidemia, and asthma through clinical measures. The main question it aims to answer is: Does the WE CARE SDOH screening and referral intervention applying an antiracism lens informed implementation strategies have the potential to reduce racial/ethnic health inequities in chronic diseases for minoritized patients?

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Single Group Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Other: WE CARE SDOH System — The WE CARE System: A family-centered, highly efficacious approach for addressing adverse SDOH in the clinical setting. Arvin Garg, MD, MPH developed and conceptualized the WE CARE (Well-Child care visit, Evaluation, Community Resources, Advocacy, Referral, Education) intervention in 2005. This approach relies on existing clinical processes and infrastructure and social service resources, thereby making implementation, dissemination, and sustainability feasible. The intervention components include brief training of the clinical team; administration of a short screening tool to parents/patients identifying their desire for help with specific unmet social needs; and provider/clinic staff access to a physical or electronic family resource book containing community- resource listings. Providers generate referrals for families who indicate that they want help with unmet social needs on the WE CARE screener. Existing staff members may assist patients in connecting to referred resources.
  • Other: Standard Pediatric Care — Standard pediatric care includes any existing screening practices, which can vary at each clinic.

Primary Outcomes

  • Blood pressure (BP) measurements (Every 3 months for up to 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-08
Completion: 2028-09-30
Eligibility
Age: Not reported
Sex: ALL
Volunteers: true
Enrollment: 68000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Massachusetts, Worcester
Collaborators: National Institute of Nursing Research (NINR), Boston University, Boston Medical Center, Family Health Center of Worcester
Contact Information
Study Contact:
Arvin Garg
4103363261‬
arvin.garg@umassmemorial.org
Jennifer Hazelton
9783370340‬
jennifer.hazelton@umassmed.edu
Arvin Garg
410-336-3261
arvin.garg@umassmemorial.org
UMass Memorial Medical Center - Hahnemann Campus
Interventions
  • Other: WE CARE SDOH System — The WE CARE System: A family-centered, highly efficacious approach for addressing adverse SDOH in the clinical setting. Arvin Garg, MD, MPH developed and conceptualized the WE CARE (Well-Child care visit, Evaluation, Community Resources, Advocacy, Referral, Education) intervention in 2005. This approach relies on existing clinical processes and infrastructure and social service resources, thereby making implementation, dissemination, and sustainability feasible. The intervention components include brief training of the clinical team; administration of a short screening tool to parents/patients identifying their desire for help with specific unmet social needs; and provider/clinic staff access to a physical or electronic family resource book containing community- resource listings. Providers generate referrals for families who indicate that they want help with unmet social needs on the WE CARE screener. Existing staff members may assist patients in connecting to referred resources.
  • Other: Standard Pediatric Care — Standard pediatric care includes any existing screening practices, which can vary at each clinic.
Study Locations (3 sites)
UMass Memorial Medical Center - Hahnemann Campus, Worcester, Massachusetts 01605 United States
Family Health Center of Worcester, Worcester, Massachusetts 01610 United States
UMass Memorial Medical Center -Benedict Family Medicine Clinic, Worcester, Massachusetts 01655 United States
Eligibility Criteria
Inclusion Criteria: * Adults and children with diagnosed chronic diseases (hypertension, diabetes mellitus, hyperlipidemia, asthma, or depression) who receive Family Medicine care at one of the study sites. * Children (\<18 years of age) with a diagnosis of asthma. * Adult patients (18 years or older) with a diagnosis of diabetes mellitus, hypertension, hyperlipidemia and/or depression. Exclusion Criteria: * In adults (\>18 years of age), those without one or more of the following diagnoses as recorded by ICD-10 codes in their EHR: hypertension, hyperlipidemia, diabetes mellitus, or depression. * In children (\<18 years of age), those without a diagnosis of asthma.
Conditions Major Depressive Disorder (MDD)
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Major Depressive Disorder (MDD) significantly impacts quality of life and health status. Standard treatments include medical, psychological, and pharmacological approaches, with physical therapy often playing a less central role. This pilot study aims to investigate the potential benefits of incorporating a physical therapy program, based on therapeutic exercise and health education, within the management of MDD in a short-stay psychiatric unit. This project will implement a physical therapy intervention consisting of twice-weekly sessions of active joint mobility exercises, strength training (body weight/elastic bands), balance exercises, and progressive muscle relaxation, integrated with health education on the benefits of physical activity for mental health and strategies for long-term adherence. Adult patients (over 18 years) diagnosed with MDD, admitted to the short-stay psychiatry unit of Royo Villanova Hospital in Zaragoza and under regular medical, psychological, and pharmacological treatment, will be recruited for this study. All participants will receive the physical therapy program in addition to their standard care. The main objective is to analyze the preliminary efficacy of a physical therapy intervention program based on health education and therapeutic exercise in improving quality of life and health status in adults with MDD during their stay in a short-stay psychiatric unit. A secondary objective is to explore the perceptions of these patients and the healthcare professionals regarding the implementation of this multimodal treatment approach, including barriers and facilitators encountered. Hypothesis: A physical therapy program integrating therapeutic exercise and health education is feasible and preliminarily effective in improving quality of life and health status in adults with MDD in a short-stay psychiatric unit and is perceived positively by both patients and healthcare professionals regarding its implementation.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Physical Therapy Program for MDD — PT program for hospitalized adults with MDD: twice-weekly, 45-min sessions integrating: 1) Active joint mobility (gentle movements for ROM). 2) Progressive strength (bodyweight/bands, low-mod intensity, major muscles). 3) Balance (stability exercises, adapted difficulty). 4) Progressive muscle relaxation (end of session). Includes health education: exercise \& mental health link (biological/psychological mechanisms), benefits of each exercise type (mood, function, QoL), post-discharge activity strategies, self-assessment, community resources in Zaragoza. Delivered by trained PTs, adaptable to individual needs.

Primary Outcomes

  • Change in Quality of Life (From enrollment to the end of treatment at 3-6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-01
Completion: 2027-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universidad San Jorge
Principal Investigators:
  • Carolina Jiménez Sánchez, Dr (STUDY_DIRECTOR) - Universidad San Jorge
  • José Lesmes Poveda López (PRINCIPAL_INVESTIGATOR) - Universidad San Jorge
Contact Information
Study Contact:
Carolina Jiménez Sánchez, Dr
+0034649612644
cjimenez@usj.es
José Lesmes Poveda López
+0034669946333
jlpoveda@usj.es
Bárbara Gómez Marco, Dr
+0034646265729
barbaramarcogomez@gmail.com
Hospital Royo Villanova
Interventions
  • Other: Physical Therapy Program for MDD — PT program for hospitalized adults with MDD: twice-weekly, 45-min sessions integrating: 1) Active joint mobility (gentle movements for ROM). 2) Progressive strength (bodyweight/bands, low-mod intensity, major muscles). 3) Balance (stability exercises, adapted difficulty). 4) Progressive muscle relaxation (end of session). Includes health education: exercise \& mental health link (biological/psychological mechanisms), benefits of each exercise type (mood, function, QoL), post-discharge activity strategies, self-assessment, community resources in Zaragoza. Delivered by trained PTs, adaptable to individual needs.
Study Locations (1 sites)
Hospital Royo Villanova, Zaragoza, Aragon 50012 Spain
Eligibility Criteria
Inclusion and Exclusion Criteria for Patients with Major Depressive Disorder (MDD): Inclusion Criteria: * Be 18 years of age or older. * Be currently admitted to the short-stay inpatient unit of the Psychiatry Department at Royo Villanova Hospital (Zaragoza). * Have a physician-confirmed diagnosis of Major Depressive Disorder (MDD) according to current diagnostic criteria (ICD-10 or DSM-5). * Be receiving regular medical, psychological, and/or pharmacological treatment for their MDD. * Not require continuous supervision and control by nursing staff during data collection and the intervention. * Have provided written informed consent to participate in the study. Exclusion Criteria: * Presence of a comorbid physical or mental illness whose clinical characteristics and/or severity impede comprehension and/or adherence to the physical therapy interventions. * Presence of a physical or mental dysfunction or disability that constitutes a total or partial contraindication for physical therapy techniques. * Legal incapacity or pregnancy. * Present a significant risk of self-harm or suicide requiring clinical management that takes precedence over study participation (this exclusion will be determined by the responsible medical team). Inclusion and Exclusion Criteria for Healthcare Professionals at Royo Villanova Hospital: Inclusion Criteria: * Be a healthcare professional (physician, nurse, physical therapist, occupational therapist, etc.) or non-healthcare staff member (nursing assistant, orderly, etc.) within the short-stay inpatient Psychiatry Department at Royo Villanova Hospital (Zaragoza). * Be actively employed under a single, permanent, or temporary employment contract throughout the duration of the physical therapy intervention implementation period. * Have provided written informed consent to participate in the study. Exclusion Criteria: * Professionals from the unit who were not actively employed under a single, permanent, or temporary employment contract throughout the entire duration of the physical therapy intervention implementation period. * Be on sick leave or parental leave during the period of qualitative data collection. * Have been transferred to another unit or healthcare center prior to the commencement of qualitative data collection.

Effect of WBT for CI With Depression

NCT06968013
Recruiting
Conditions Chronic Insomnia, Depression Disorders
Phase NA
Enrollment 84
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This randomized controlled trial aims to explore the therapeutic effects of Well-Being Therapy (WBT) on patients with Chronic Insomnia accompanied by depressive symptoms.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Well-Being Therapy — Participants will undergo Well-Being Therapy (WBT) sessions once daily for 50 minutes over a period of six weeks. The core elements of WBT include prompting participants to identify instances of well-being, contextualize these experiences using a structured diary, and recognize as well as restructure thoughts, beliefs, and behaviors that prematurely disrupt well-being. Additionally, the specific components of the six dimensions of the Psychological Well-Being (PWB) scale-autonomy, environmental mastery, personal growth, positive relations with others, purpose in life, and self-acceptance-are systematically integrated into different therapy sessions
  • Behavioral: Sleep Hygiene Education — Participants will receive Sleep Hygiene Education (SHE) alone for 6 weeks. SHE involves education on maintaining consistent sleep schedules, creating a sleep-conducive environment, reducing stimulant use (e.g., caffeine, alcohol), and promoting healthy daily routines to improve sleep quality.

Primary Outcomes

  • Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) Score at 6 Weeks (Baseline and Week 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-01
Completion: 2025-11-01
Eligibility
Age: 8 Years and older
Sex: ALL
Volunteers: false
Enrollment: 84 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xuanwu Hospital, Beijing
Contact Information
Study Contact:
Hongxing Wang, MD & PhD
+86 13911127385
wanghongxing@xwh.ccmu.edu.cn
Hongxing Wang, MD & PhD
+86 13911127385
wanghongxing@xwh.ccmu.edu.cn
Xuanwu Hospital, Capital Medical University
Interventions
  • Behavioral: Well-Being Therapy — Participants will undergo Well-Being Therapy (WBT) sessions once daily for 50 minutes over a period of six weeks. The core elements of WBT include prompting participants to identify instances of well-being, contextualize these experiences using a structured diary, and recognize as well as restructure thoughts, beliefs, and behaviors that prematurely disrupt well-being. Additionally, the specific components of the six dimensions of the Psychological Well-Being (PWB) scale-autonomy, environmental mastery, personal growth, positive relations with others, purpose in life, and self-acceptance-are systematically integrated into different therapy sessions
  • Behavioral: Sleep Hygiene Education — Participants will receive Sleep Hygiene Education (SHE) alone for 6 weeks. SHE involves education on maintaining consistent sleep schedules, creating a sleep-conducive environment, reducing stimulant use (e.g., caffeine, alcohol), and promoting healthy daily routines to improve sleep quality.
Study Locations (1 sites)
Xuanwu Hospital, Capital Medical University, Beijing, 100053 China
Eligibility Criteria
Inclusion Criteria: 1. Diagnosed with Insomnia Disorder according to DSM-5 criteria, with a duration of at least 3 months. 2. Pittsburgh Sleep Quality Index (PSQI) total score \> 5. 3. Age 8 years or older. 4. Educational level of at least junior high school. 5. Voluntarily agree to participate and provide written informed consent. 6. Presence of depressive symptoms, defined as Hamilton Depression Scale (HAMD) score ≥ 16. Exclusion Criteria: 1. Presence of severe physical illnesses or major psychiatric disorders, or at risk of suicide. 2. Diagnosed or suspected of having sleep breathing disorders, restless legs syndrome, circadian rhythm sleep disorders, or engaged in shift work. 3. Pregnant or breastfeeding women. 4. Currently undergoing any psychological therapy.